🚨Trade Alert 🚨 SNGX

🚨Trade Alert 🚨 SNGX͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ This little-known NASDAQ biopharma company is advancing science, helping patients, and firing on all cylinders to build shareholder value… Greetings Investors, Innovation is alive and well in the biopharma industry. And while many of the giants focus on big diseases, there is a big arena filled with unmet medical needs that also need attention. Why are niche markets profitable? Less competition. This brings attention to a late-stage biopharmaceutical company that is focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. By focusing on a niche space, emerging biopharma player Soligenix, Inc. (Nasdaq: SNGX) could potentially capitalize significantly! NASDAQ: SNGX currently has a “STAY LONG” rating from [AmericanBulls.com]( and NASDAQ lists a [$3 price target]( for the stock! It also should be noted that the company has a relatively tiny trading float, per [Yahoo Finance.]( This late clinical-stage, publicly traded company has TWO unique business segments: - a Specialized Biotherapeutics segment dedicated to the development of products in oncology and inflammation, such as [cutaneous T-cell lymphoma]( or CTCL. - a Public Health Solutions segment developing heat-stable vaccines for emerging infectious diseases, like Ebola and in the area of biodefense to protect the World from potential bioterrorism, such as from lethal ricin attacks. The company’s Public Health Solutions business segment includes CiVax(TM), the company’s vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). Covid-19 is far from over. The pandemic helped to push Moderna’s share price to unprecedented heights as the world scrambled for their vaccine. On the Specialized BioTherapeutics business front, NASDAQ: SNGX is developing and moving toward potential commercialization of HyBryte(TM) (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). One of the most common forms of T-cell lymphoma is cutaneous T-cell lymphoma (CTCL), a general term for T-cell lymphomas that involve the skin. CTCL can also involve the blood, lymph nodes, and other internal organs. The company recently reached a pivotal milestone! NASDAQ: SNGX reported positive results from the compatibility study of HyBryte in the treatment of cutaneous T cell lymphoma (CTCL). According to the company’s CEO Christopher J. Schaber, PhD, “The [HyBryte™]( compatibility clinical study importantly established that any commercially viable light device capable of producing visible light of an appropriate and consistent wavelength (500 to 650 nm) was suitable for use with HyBryte™ (topical synthetic hypericin) and extended the pharmacokinetic (PK) profile by showing that only very minute quantities of the drug are systemically absorbed, which is important when treating a rare and chronic cancer with no cure, like CTCL.” In addition to meeting these important objectives, the efficacy demonstrated in this study strongly substantiated the results of NASDAQ: SNGX’s successful Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study. The treatment response data following 8 weeks of twice weekly HyBryte™ therapy reinforced the positive results demonstrated in the FLASH trial, despite the fact that patients in the compatibility study were specifically selected to have more extensive disease consistent with its potential commercial use. “Overall, the findings from this study further supported HyBryte™ as a safe and effective treatment in CTCL, where essentially all of the current treatment options have significant safety issues associated with them,” added Dr. Schaber. With a successful Phase 3 study completed, regulatory approval is being sought and commercialization activities for this product candidate are being advanced initially in the U.S! Soligenix, Inc. (Nasdaq: SNGX) may be one of the most promising biopharma companies for your watch list in 2023! []( Soligenix, Inc. NASDAQ: SNGX Rising to the challenges of rare disease treatment! Company Overview: Soligenix has expertise in the development of orphan and unmet medical need indications including preclinical, manufacturing, regulatory, and clinical expertise. Soligenix has a number of Public Health programs, funded entirely by government grants and contracts, which focus on infectious disease and biodefense applications, including our most advanced vaccination program to prevent [ricin poisoning](. Investment Highlights: Development programs in the company’s Specialized Biotherapeutics business segment include: - Expansion of synthetic hypericin (SGX302) into psoriasis, the company’s first-in-class innate defense regulator (IDR) technology. The company is currently enrolling in a small Phase 2a study evaluating [SGX302]( hypericin), which is the same active ingredient that is in HyBryte™, for the treatment of mild-to-moderate psoriasis. - Dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer - Proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation including pediatric Crohn's disease (SGX203) The company’s Public Health Solutions business segment also includes: - Active development programs for RiVax(R), its ricin toxin vaccine candidate - Vaccine programs targeting filoviruses (such as Marburg and Ebola) The development of the company’s vaccine programs incorporates the use of NASDAQ: SNGX’s proprietary heat stabilization platform technology, known as ThermoVax(R). To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA), and the Biomedical Advanced Research and Development Authority (BARDA). Recent Developments: On May 1, 2023, Soligenix [announced]( it has entered into an exclusive option agreement with Silk Road Therapeutics, which grants the company the right to acquire a novel topical formulation of pentoxifylline (PTX), a non-biological anti-TNF-alpha inhibitor, for the treatment of mucocutaneous ulcers in patients suffering from Behçet’s Disease (BD). BD is a rare multisystem inflammatory vasculitis with no cure. There are approximately 18,000 people living with it in the U.S. and about 80,000 in Europe, however, there are as many as 1,000,000 people worldwide living with this painful and life altering disease. “The option agreement with Silk Road grants the Company the right to acquire this novel muco-adherent topical formulation of Pentoxifylline or PTX which not only has the potential to fill a significant void in the current treatment armamentarium for BD, but adds to Soligenix robust rare disease pipeline with another later clinical stage asset,” said CEO Christopher J. Schaber, PhD. Subsequently on May 1, 2023, the company [announced]( the appointment of Dr. Timothy Coté to its Board of Directors. Dr. Cote worked at the NIH, CDC and FDA for 23 years, including as the Director of the FDA Office of Orphan Products Development, in which he implemented the U.S. Orphan Drug Act and personally signed decisions on more than 1,400 orphan drug designation applications. Following his tenure at the FDA, Dr. Coté served as CEO of Cote Orphan, a consultancy firm that was sold to IQVIA in 2017. He is currently the CEO of Silk Road Therapeutics, from which Soligenix signed the exclusive option to purchase the novel topical formulation of pentoxyfilline (PTX). On May 4, 2023, Soligenix, Inc. (NASDAQ:SNGX) [announced]( results from a compatibility study of HyBryte in the treatment of cutaneous T cell lymphoma (CTCL) using the commercially ready Daavlin Series 7 visible light device. The purpose of the study was to establish that any light device capable of producing visible light (500 to 650 nm) was suitable for use with HyBryte and to extend the pharmacokinetic profile using a recently developed, more sensitive hypericin assay. Both of those objectives were met in the study. In addition, the treatment response rate of 22% following eight weeks of twice-weekly treatment recapitulated the results of the Phase 3 FLASH study. On May 11, 2023, Soligenix announced that the U.S. FDA has granted a Type A meeting to discuss the design of a second Phase 3 trial to evaluate HyBryte in the treatment of CTCL. This will be a following up meeting to the Type A meeting conducted earlier this year to discuss the refusal to file (RTF) letter previously issued in regards to the company’s new drug application (NDA) for HyBryte for the treatment of early stage CTCL. At that meeting, the FDA stated it is going to require positive results from a second clinical trial in addition to the positive results from the Phase 3 FLASH study in order to accept an NDA filing. The company is expected to announce details of the second Phase 3 trial when it has greater clarity on next steps. On May 15, 2023, Soligenix announced financial results for the first quarter of 2023. The company reported revenues of $0.3 million for the first quarter of 2023, compared to $0.2 million for the first quarter of 2022. The revenues are derived from government contracts and grants to support the development of RiVax® along with grants to support the development of SGX943, ThermoVax®, and CiVax®. R&D expenses for the first quarter of 2023 were $1.0 million, compared to $1.7 million for the first quarter of 2022. In Summary… NASDAQ: SNGX is a company to have your attention on. The company is in a good financial position and could be at supreme value given all of the developments happening! NASDAQ: SNGX is advancing HyBryte™ in CTCL, while also continuing to move forward with SGX302 in psoriasis and PTX in BD. While doing this, the company continues to remain vigilant to identify potential opportunities to increase shareholder value as quickly as possible, including, but not limited to, potential business partnerships and/or merger and acquisition!As detailed in the company’s [corporate presentation]( NASDAQ: SNGX estimates the total addressable global market potential across both its business segments to be approximately $2 billion.“When you look at our pipeline, current stock price and market cap, the potential upside is significant, in my opinion,” remarked CEO Christopher J. Schaber, PhD. There are a number of 2023 milestones that NASDAQ: SNGX anticipates achieving across their two business segments. With a $3 price target, make sure the stock is high on your radar, and keep a close eye out for any more developments! Copyright 2023 © SCDalerts.com is owned and operated by the owner of SCD Media LLC. Disclaimer and Privacy For more Information please contact info@smallcapsdaily.com This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security. SCD Media, its managers, its employees, affiliates, and assigns (collectively "The Company") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above. To the maximum extent permitted by law, the Company disclaims all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete, or unreliable, or result in any investment or other losses. You received this message as part of your subscription to SCD Alerts. SCD Alerts is a financial news and information website. We do not directly sell any products or offer any personal financial advice, nor do we advocate the purchase or sale of any security or investment for any specific individual. We also do not make any guarantee or warranty about what is advertised above. If you have questions or concerns about a product you’ve seen in one of our emails, we encourage you to reach out to that company directly. Disclaimer – Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated, and edited by SCD Media. Any wording found in this e-mail or disclaimer referencing “I” or “we” or “our” or “SCD” refers to SCD Media. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares, we will list the information relevant to the stock and the number of shares here. We do not own any shares in SNGX. We have been currently compensated up to Twenty Five Thousand Dollars Cash ($25,000) via bank wire transfer from SNGX for a 1 Day Marketing Program regarding SNGX with a start date of 7/10/2023. SCD’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding our alerts. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non- compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, SCD often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. Small Caps Daily 1334 Northampton St Easton, PA 18042 © 2023 | All rights reserved. [Unsubscribe](. [Twitter] [Facebook] [Instagram]